topical steroids and cyclosporin-A

PreclinicalSmall molecule

topical steroids and cyclosporin-A is one of 6 small molecule programs targeting Keratoconjunctivitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

KeratoconjunctivitisActive, not recruiting

KeratoconjunctivitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Keratoconjunctivitis

#DrugCompanyPhaseTrials

Neoral

Novartis

Approved

—2

Prograf

VVeloxis Pharmaceuticals

Approved

2 3

Lotemax

PPharmos

Approved

2 4

Decadron

AAspen Global Incorporated

Approved

1 5

Betadine

BBecton, Dickinson and Company

Preclinical

1 6

topical steroids and cyclosporin-A

AAmeera Gamal Abdelhameed

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Keratoconjunctivitis1 trial

Topical Steroids and Cyclosporin-A for COVID-19 Keratoconjunctivitis

Unknown status·AAmeera Gamal Abdelhameed·N/A·NCT04451239·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for topical steroids and cyclosporin-A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — topical steroids and cyclosporin-A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for topical steroids and cyclosporin-A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ameera Gamal Abdelhameed company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAmeera Gamal Abdelhameed

topical steroids and cyclosporin-A

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Keratoconjunctivitis1 trial

References

Drug Info

Quick Facts

Related News